|
Antigen specific
|
mAb
|
SARS-CoV-2
|
SARS-CoV
|
|---|
|
RBD KD (nM)
|
Receptor blocking IC50 (ng/ml)
|
Pesudo virus IC50 (ng/ml)
|
Authentic virus IC50 (ng/ml)
|
RBD KD (nM)
|
Receptor blocking IC50 (μg/ml)
|
Pesudo virus IC50 (μg/ml)
|
|---|
|
SARS-CoV-2 specific
|
24-2K
|
6.1
|
63.4
|
17.0
|
171.0
|
N.D.
|
N.D.
|
N.D.
|
|
24-1L
|
7.3
|
7.0
|
5.1
|
229.0
|
N.D.
|
N.D.
|
N.D.
|
|
24-11K
|
2.7
|
2.0
|
5.6
|
74.0
|
N.D.
|
N.D.
|
N.D.
|
|
24-12K
|
2.2
|
7.0
|
8.2
|
162.0
|
N.D.
|
N.D.
|
N.D.
|
|
25-C4
|
1.2
|
43.2
|
50.0
|
112.0
|
N.D.
|
N.D.
|
N.D.
|
|
25-C5
|
1.0
|
49.0
|
33.0
|
419.0
|
N.D.
|
N.D.
|
N.D.
|
|
25-C8
|
2.8
|
68.6
|
68.0
|
345.0
|
N.D.
|
N.D.
|
N.D.
|
|
25-C9
|
2.2
|
138.9
|
8.0
|
146.0
|
N.D.
|
N.D.
|
N.D.
|
|
25-B5
|
3.5
|
2.0
|
1.0
|
91.0
|
N.D.
|
N.D.
|
N.D.
|
|
25-F8
|
4.0
|
79.9
|
8.7
|
345.0
|
N.D.
|
N.D.
|
N.D.
|
|
25-G7
|
0.5
|
29.0
|
10.6
|
55.0
|
N.D.
|
N.D.
|
N.D.
|
|
26-40K
|
6.8
|
2.2
|
4.2
|
21.0
|
N.D.
|
N.D.
|
N.D.
|
|
26-34L
|
15.9
|
7.0
|
10.0
|
171.0
|
N.D.
|
N.D.
|
N.D.
|
|
26-45K
|
3.9
|
3.7
|
2.7
|
162.0
|
N.D.
|
N.D.
|
N.D.
|
|
28-15L
|
2.7
|
7.0
|
35.0
|
171.0
|
N.D.
|
N.D.
|
N.D.
|
|
28-8L
|
11.9
|
4.1
|
4.0
|
38.0
|
N.D.
|
N.D.
|
N.D.
|
|
CB6
|
10.7
|
7.0
|
9.7
|
73.0
|
N.D.
|
N.D.
|
N.D.
|
|
Crossing
|
25-D9
|
0.4
|
356.1
|
14.0
|
345.0
|
7.2
|
2.2
|
0.9
|
|
25-F7
|
1.2
|
26.5
|
22.0
|
1883.0
|
4.9
|
5.3
|
5.0
|
|
28-26K
|
0.1
|
89.3
|
25.0
|
330.0
|
4.9
|
3.8
|
3.5
|
|
CR3022
|
57.8
|
>15000
|
>25000
|
N.D.
|
0.9
|
1.9
|
0.4
|
|
S309
|
<1E-3
|
>15000
|
60.2
|
N.D.
|
<1E−3
|
>15
|
0.03
|
- N.D., not determined; CB6, CR3022, and S309 were used as control [36, 38, 39]
